StockData
Immunic, Inc. logo

Immunic, Inc. (IMUX) stock

IMUXNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 13, 2026Score 6/30
$6.99−0.40 (-5.41%)

Close on Nov 20, 2026Market cap $95.37MP/E –Yield 0.00%

Immunic free cash flow

Free cash flow is cash from operations minus capital expenditures: the cash available for dividends, buybacks, debt repayment or acquisitions.

Immunic's free cash flow for the twelve months ending Jun 30, 2026 was -$88.05M. For fiscal 2025 it was -$85.97M. The highest annual figure on record is -$9.51M in fiscal 2012.

Annual free cash flow

PeriodPeriod endValueChange
FY2025Dec 31, 2025-$85.97M–
FY2024Dec 31, 2024-$85.03M–
FY2023Dec 31, 2023-$71.16M–
FY2022Dec 31, 2022-$65.26M–
FY2021Dec 31, 2021-$83.30M–
FY2020Dec 31, 2020-$46.27M–
FY2019Dec 31, 2019-$28.60M–
FY2018Dec 31, 2018-$9.77M–
FY2017Dec 31, 2017-$41.08M–
FY2016Dec 31, 2016-$36.33M–
FY2015Dec 31, 2015-$52.29M–
FY2014Dec 31, 2014-$42.23M–
FY2013Dec 31, 2013-$30.13M–
FY2012Dec 31, 2012-$9.51M–

Quarterly free cash flow

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q2 FY2026Jun 30, 2026-$31.25M–
Q1 FY2026Mar 31, 2026-$17.30M–
Q4 FY2025Dec 31, 2025-$19.29M–
Q3 FY2025Sep 30, 2025-$20.21M–
Q2 FY2025Jun 30, 2025-$24.65M–
Q1 FY2025Mar 31, 2025-$21.82M–
Q4 FY2024Dec 31, 2024-$22.97M–
Q3 FY2024Sep 30, 2024-$20.85M–
Q2 FY2024Jun 30, 2024-$17.22M–
Q1 FY2024Mar 31, 2024-$24.00M–
Q4 FY2023Dec 31, 2023-$14.19M–
Q3 FY2023Sep 30, 2023-$17.36M–
Q2 FY2023Jun 30, 2023-$20.00M–
Q1 FY2023Mar 31, 2023-$19.62M–
Q4 FY2022Dec 31, 2022-$15.10M–
Q3 FY2022Sep 30, 2022-$13.67M–
Q2 FY2022Jun 30, 2022-$15.79M–
Q1 FY2022Mar 31, 2022-$20.69M–
Q4 FY2021Dec 31, 2021-$23.70M–
Q3 FY2021Sep 30, 2021-$17.62M–
Q2 FY2021Jun 30, 2021-$29.02M–
Q1 FY2021Mar 31, 2021-$12.96M–
Q4 FY2020Dec 31, 2020-$13.99M–
Q3 FY2020Sep 30, 2020-$11.97M–
Q2 FY2020Jun 30, 2020-$9.28M–
Q1 FY2020Mar 31, 2020-$11.03M–
Q4 FY2019Dec 31, 2019-$6.29M–
Q3 FY2019Sep 30, 2019-$5.99M–
Q2 FY2019Jun 30, 2019-$11.00M-222.1%
Q1 FY2019Mar 31, 2019-$5.32M–
Q4 FY2018Dec 31, 2018-$3.47M–
Q3 FY2018Sep 30, 2018-$2.09M–
Q2 FY2018Jun 30, 2018$9.01M–
Q1 FY2018Mar 31, 2018-$13.22M–
Q4 FY2017Dec 31, 2017-$10.03M–
Q3 FY2017Sep 30, 2017-$9.59M–
Q2 FY2017Jun 30, 2017-$10.28M–
Q1 FY2017Mar 31, 2017-$11.18M–
Q4 FY2016Dec 31, 2016-$9.22M–
Q3 FY2016Sep 30, 2016-$8.16M–

More Immunic figures

See a number that looks wrong?